Skip to main content
. 2018 Feb;145(2):210–218. doi: 10.1017/S0031182017001901

Fig. 4.

Fig. 4.

The three different scaffolds for TgCDPK1 inhibitors (a) pyrazolpyrimidines, (b) acylbenzimidazoles and (c) 5-aminopyrazole-4-carboxamide. CDPKs, calcium-dependent protein kinases.